<DOC>
	<DOCNO>NCT00357825</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness [ S , S ] -Reboxetine patient fibromyalgia .</brief_summary>
	<brief_title>A Trial Assessing The Effectiveness Safety S , S-Reboxetine Patients With Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Reboxetine</mesh_term>
	<criteria>At screen patient must meet ACR criterion fibromyalgia ( i.e . widespread pain least 3 month , pain least 11 18 specific tender point site ) . At screen randomization , patient must score &gt; /=40mm Visual Analog Scale ( VAS ) ShortFormMcGill Pain Questionnaire ( SFMPQ ) . Patients severe pain ( e.g . DPN PHN ) may confound assessment selfevaluation pain associate fibromyalgia . Patients severe hepatic impairment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>